Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

44.74USD
18 Aug 2017
Change (% chg)

$-0.24 (-0.53%)
Prev Close
$44.98
Open
$44.87
Day's High
$45.82
Day's Low
$43.85
Volume
316,245
Avg. Vol
230,734
52-wk High
$57.33
52-wk Low
$9.40

Select another date:

Tue, Aug 8 2017

BRIEF-Esperion announces proposed public offering of common stock

* Esperion announces proposed public offering of common stock

BRIEF-Co announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

* Says Esperion announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

BRIEF-Esperion reports initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

* Esperion announces initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

BRIEF-Esperion reports Q1 net loss per common share $1.80

* Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results

BRIEF-Boxer Capital reports 5.3 pct passive stake in Esperion Therapeutics

* Boxer Capital LLC reports 5.3 percent passive stake in Esperion Therapeutics Inc as of March 20 - SEC filing Source: (http://bit.ly/2mZu8Mb) Further company coverage:

BRIEF-Esperion announces FDA confirmation to approval for an LDL-C lowering indication for bempedoic acid

* Esperion announces fda confirmation regarding regulatory pathway to approval for an ldl-c lowering indication for bempedoic acid

BRIEF-Esperion initiates of phase 2 triplet oral therapy study

* Esperion announces initiation of phase 2 triplet oral therapy study of bempedoic acid/ezetimibe/atorvastatin

BRIEF-Esperion posts Q4 loss per share $1.29

* Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results

Select another date: